Are you looking for the latest scoop on business news that will give you a competitive edge in the market? Look no further than the Extreme Investor Network, where we provide unique insights and analysis that you won’t find anywhere else.
In a groundbreaking development, Novavax has entered into a multibillion-dollar deal with Sanofi to co-commercialize its Covid vaccine starting next year and develop combination shots targeting both the coronavirus and the flu. This collaboration marks a significant turning point for Novavax, as it allows the company to lift its “going concern” warning and expand its reach in the vaccine market.
Under the terms of the deal, Sanofi will pay Novavax $500 million upfront and up to $700 million in milestone payments for development, regulatory, and launch milestones. Additionally, Sanofi will have access to Novavax’s Covid shot and Matrix-M adjuvant technology to develop new vaccine products. This partnership not only benefits Novavax financially but also aligns with its mission of improving global public health.
Sanofi will take a less than 5% stake in Novavax as part of the deal, further solidifying the partnership between the two companies. With this collaboration, Novavax expects to accelerate the development of new vaccines and expand patient access to its Covid shot.
In addition to the deal with Sanofi, Novavax is gearing up to start a late-stage trial on its own combination vaccine targeting Covid and the flu, as well as its standalone flu shot. This trial will now include both potential licensable vaccines, thanks to the partnership with Sanofi.
Stay ahead of the curve with Extreme Investor Network’s exclusive coverage of this groundbreaking deal between Novavax and Sanofi. Our in-depth analysis and expert insights will give you a comprehensive understanding of the latest developments in the business world. Subscribe now to access our premium content and stay informed about the most important business news.
